Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
Want to see DNTH full AI Analyst Report?
Trend: â–² Hedge Funds Increased Holdings by 3.9M Shares Last Quarter
Hedge Fund Holdings in DNTH
Based on the 13F filings of 488 Hedge Funds submitted to the SEC.
See how hedge fund holdings have changed over the past year. The columns represent the number of shares owned by hedge funds.
Hedge Fund Confidence Signal
Very Positive'%3E%3C/stop%3E%3Cstop offset='100%25' stop-color='rgba(59, 146, 255,0.1)'%3E%3C/stop%3E%3C/linearGradient%3E%3C/defs%3E%3Cpath d='M10,90 A60,60 0 0,1 170,90' fill='none' stroke='url(%23gradient)' stroke-width='20'%3E%3C/path%3E%3C/svg%3E)
Sold
Bought
A unique signal which shows hedge fund sentiment according to recent transactions.
Hedge Fund Activity​
Activity
Any
Star Ranking
Any
FAQ
Which hedge funds hold Dianthus Therapeutics?
The hedge funds that hold the most shares in Dianthus Therapeutics are Stephen A. Schwarzman, Kevin Molloy and Jacob Mitchell.
Are hedge funds buying or selling DNTH?
In the last quarter hedge funds have Increased their holdings in Dianthus Therapeutics by 3.9M shares.
Where can I see a list of the best rated hedge funds?
You can see a list of the best hedge funds here.
Who is the best-performing hedge fund manager?
The top-rated hedge fund managers can be seen here: Top Hedge Fund Managers
Does Warren Buffet hold shares in Dianthus Therapeutics stock?
Warren Buffet currently does not own shares in Dianthus Therapeutics.
What is a 13F filing, and how does it help investors?
A 13F form, also known as a "Report of Investment Manager," is a quarterly report that investment advisors registered with the Securities and Exchange Commission (SEC) must file if they manage at least $100 million in assets. The 13F form lists all of the publicly traded securities that the investment advisor owns as of the end of the reporting period. To read more about the 13F, click here